{"product_id":"exactsciences-swot-analysis","title":"Exact Sciences SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Strategic Toolkit Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExact Sciences sits at the crossroads of innovative cancer diagnostics and volatile reimbursement dynamics—our concise SWOT preview highlights its technological edge, scaling challenges, and market catalysts; purchase the full SWOT analysis for a research-backed, editable Word and Excel package that equips investors, strategists, and advisors with actionable insights and financial context to plan, pitch, and invest confidently.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position in Non-Invasive Screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCologuard, Exact Sciences' stool DNA test, screened over 7 million patients through 2025, anchoring the company as the leading non-invasive CRC (colorectal cancer) screening option and generating steady recurring revenue—Cologuard contributed roughly $1.6 billion in 2025 product revenue. This scale creates a competitive moat, lowers per-test costs, and underpins ongoing R\u0026amp;D funding. First-mover status locked Cologuard into major clinical guidelines and physician workflows, sustaining market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Precision Oncology Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Oncotype DX genomic tests remain a global standard in breast and prostate cancer care, with ~1.3M cumulative assays performed by Exact Sciences through 2024 and payer coverage exceeding 90% for key indications.\u003c\/p\u003e\n\u003cp\u003eClinical utility—reducing chemotherapy use by ~30% in ER+\/HER2- early breast cancer—boosts clinician trust and supports premium pricing, contributing roughly $650M in 2024 revenue from the precision oncology segment.\u003c\/p\u003e\n\u003cp\u003eThis precision-medicine lineup diversifies Exact’s revenue away from colorectal screening (Cologuard), lowering single-product risk and stabilizing gross margins amid screening-market cyclicality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExact Sciences operates one of the diagnostic sector’s largest commercial engines, with a salesforce reaching over 300,000 healthcare providers and driving 2024 U.S. screening test revenue of $2.1 billion, enabling rapid rollout of new assays and consistent primary care loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Capacity Automated Laboratory Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpexact sciences operates automated labs processing over million tests annually driving consistent qc and\u003e99% assay reproducibility; this scale lowers per-test cost versus smaller rivals and supports payer and clinician trust.\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e\u0026gt;10M tests\/year (2024)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;99% assay reproducibility\u003c\/li\u003e\n\u003cli\u003eSignificant per-test cost advantage vs emerging labs\u003c\/li\u003e\n\n\u003c\/pexact\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Intellectual Property and R and D Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpexact sciences holds over issued and pending patents worldwide its proprietary biomarkers testing methods shield cologuard next-gen plus from generic entrants.\u003e\n\u003cpthe company invested million in r fiscal enabling iterative product upgrades and the september launch of cologuard plus with improved sensitivity for advanced adenomas.\u003e\n\u003cpthis sustained r spend and patent depth position exact through to lead noninvasive colorectal cancer screening expand molecular offerings.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ patents issued\/pending\u003c\/li\u003e\n\u003cli\u003e$199M R\u0026amp;D spend in 2024\u003c\/li\u003e\n\u003cli\u003eCologuard Plus launched Sep 2024\u003c\/li\u003e\n\u003cli\u003eHigher sensitivity vs prior generation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pthe\u003e\u003c\/pexact\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Leader: Cologuard \u0026gt;7M Patients, $1.6B 2025 Revenue; 10M+ Tests\/yr, 200+ Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarket-leading Cologuard screened \u0026gt;7M patients through 2025, generating ~$1.6B product revenue in 2025; Oncotype DX delivered ~1.3M cumulative assays through 2024 and ~90% payer coverage; automated labs processed \u0026gt;10M tests\/year (2024) with \u0026gt;99% reproducibility; 200+ patents and $199M R\u0026amp;D in 2024 funded Sept 2024 Cologuard Plus launch.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard patients (through 2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard revenue (2025)\u003c\/td\u003e\n\u003ctd\u003e~$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncotype DX assays (through 2024)\u003c\/td\u003e\n\u003ctd\u003e~1.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomated lab throughput (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10M tests\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssay reproducibility\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$199M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard Plus launch\u003c\/td\u003e\n\u003ctd\u003eSep 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Exact Sciences, highlighting its diagnostic innovation and market share strengths, operational and reimbursement vulnerabilities, growth opportunities in screening and international expansion, and competitive, regulatory, and payer-related threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise Exact Sciences SWOT matrix for quick, visual alignment on diagnostic market strengths, risks, and strategic opportunities to streamline executive decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersistent Challenges with GAAP Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite revenue rising 18% to $3.4bn in FY2024, Exact Sciences reported GAAP net losses of $412m in 2024 and $498m in 2023, showing inconsistent profitability.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D was $447m in 2024 and sales \u0026amp; marketing $1.1bn, keeping operating margins negative and cash EPS pressured.\u003c\/p\u003e\n\u003cp\u003eInvestors press for a shift from growth to margin expansion; management targets positive adjusted EBITDA by 2026 but GAAP break-even remains uncertain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Revenue Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 60% of Exact Sciences' fiscal 2024 revenue came from Cologuard, so the company is highly exposed to shifts in the colorectal cancer screening market.\u003c\/p\u003e\n\u003cp\u003eRegulatory changes or a competitor's superior noninvasive test could cut adoption and margins, hitting valuation—Cologuard accounted for roughly $1.9 billion of $3.2 billion revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eManagement is investing in diversification (oncology assays, liquid biopsies), but the core screening business still drives cash flow and near-term growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevated Customer Acquisition Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe sales and marketing spend to sustain Cologuard's 2024 US market share exceeded $300M, keeping the test top-of-mind with primary care physicians and funding outreach that drives patient compliance rates (~45% return rate), so ongoing investment is exceptionally high.\u003c\/p\u003e\n\u003cp\u003eThose annual customer-acquisition costs restrict capital for other strategic moves and limited down-payment ability on the roughly $1.6B long-term debt at year-end 2024, constraining short-term financial flexibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependency on Third-Party Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExact Sciences' revenue is highly sensitive to Medicare and private insurer reimbursement; in 2024 Medicare accounted for about 35% of U.S. screening tests, so policy shifts bite revenue quickly.\u003c\/p\u003e\n\u003cp\u003ePrice pressure or tightened coverage criteria—like a 10–20% cut scenario—could shave gross margins and slow the 2023–2024 5%–10% revenue growth trajectory.\u003c\/p\u003e\n\u003cp\u003eNegotiations with a concentrated payer market demand heavy legal and admin spend; Exact reported selling, general \u0026amp; admin of $1.4B in 2024, reflecting that burden.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% tests tied to Medicare (2024)\u003c\/li\u003e\n\u003cli\u003eSG\u0026amp;A $1.4B (2024)\u003c\/li\u003e\n\u003cli\u003e10–20% price cut → material margin risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistical Complexity of Sample Collection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe physical logistics for Exact Sciences’s stool-based tests are costlier and more failure-prone than blood or digital alternatives; in 2024 the company reported supply-chain and logistics expenses contributing to its 9% gross-margin pressure versus peers.\u003c\/p\u003e\n\u003cp\u003eSamples need temperature control and tracked returns, raising per-test fulfillment costs—industry estimates put mail-back failure rates at 2–5% and incremental per-sample logistics cost at $10–25 versus $2–5 for blood draw.\u003c\/p\u003e\n\u003cp\u003eScaling this network requires capital: Exact Sciences spent about $300–400M annually on operations and fulfillment in recent years, exposing margins if volume growth slows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher per-test logistics cost: $10–25 vs $2–5\u003c\/li\u003e\n\u003cli\u003eMail-return failure: 2–5%\u003c\/li\u003e\n\u003cli\u003eAnnual ops\/fulfillment spend: ~$300–400M (2023–24)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCologuard Reliance, Persistent Losses and $1.6B Debt Crimp Margin Recovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy reliance on Cologuard (~60% of FY2024 revenue, ~$1.9B of $3.2B), persistent GAAP losses ($412M in 2024), high S\u0026amp;M and SG\u0026amp;A ($1.1B and $1.4B in 2024), large ops\/fulfillment costs ($300–400M), payer\/reimbursement sensitivity (Medicare ~35% of tests), and ~$1.6B long-term debt constrain margin recovery and strategic flexibility.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCologuard share\u003c\/td\u003e\n\u003ctd\u003e~60% ($1.9B)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP loss\u003c\/td\u003e\n\u003ctd\u003e$412M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eS\u0026amp;M \/ SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.1B \/ $1.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOps spend\u003c\/td\u003e\n\u003ctd\u003e$300–400M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare exposure\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term debt\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eExact Sciences SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview is the actual Exact Sciences SWOT analysis document you’ll receive after purchase—no placeholders, just the full professional report ready for use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752370024825,"sku":"exactsciences-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/exactsciences-swot-analysis.png?v=1772240137","url":"https:\/\/growthsharematrix.com\/products\/exactsciences-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}